Gujarat Themis Biosyn Ltd

The transcript does not mention any current or planned fundraising through debt or equity. Specifically: - There is no discussion or indication of raising funds via equity or debt during the call. - The company focuses on using internal resources and capex plans for growth (INR 200 crores over next 2-3 years). - Capex expenditures (INR 14 crores spent, INR 13 crores in CWIP) indicate ongoing investments funded internally. - Management emphasizes ROI-based expansion rather than targeting fundraising. - Investor relations are available for follow-up, but no mention of fundraising queries or plans. Hence, based on this transcript, Gujarat Themis Biosyn Limited has not announced any current or future fundraising via debt or equity.

- The company has a capex plan of around INR 200 crores over the next few years. - Capex is divided into three key areas: R&D center, API block, and fermentation block. - The API block and R&D labs are expected to be operational by June-July of the current financial year. - Fermentation block expansion (additional 550 cubic meters capacity) will be completed by June-July of the next financial year (FY 2024). - INR 40 crores of the API block capex is expected to be spent by July. - Advances have been paid to capital equipment suppliers, with expenditures to be capitalized as assets progress. - The capex focus prioritizes ROI and efficient project completion over just turnover growth. - Strategic aim includes expanding product basket through new APIs and fermentation products to diversify revenue sources.

- The company is targeting about 25% growth in sales/revenue for the next financial year (FY 2024) (Page 17, Sachin Patel). - Sales volumes have been consistent, with production maintained at about 75-100% capacity, expecting to run at 100% capacity this year (Page 7). - Tuberculosis tender-driven market delays have impacted recent sales, especially Rifa-S, but tenders are expected to open in next two quarters, leading to significant volume increase (Pages 4, 6, 7). - The new API block, expected to be operational by June-July 2023, will aid in achieving 25-30% growth and diversify product base (Page 10). - The company is expanding fermentation capacity from 450 to 1000 cubic meters and increasing R&D efforts, which supports future growth (Pages 4, 17). - Emphasis on ROI for new projects over turnover indicates measured scaling with a focus on profitability (Page 9).

- The company is targeting approximately 25% growth in business for the next financial year (FY24) as stated by Sachin Patel. - Despite sales fluctuations in Q3 due to tender delays, production levels remain high, with the expectation that tenders will open and boost volumes soon. - Nine-month revenue and profit for the current fiscal year have already surpassed previous financial year levels. - EBITDA margin for the nine months stands at 49.1%, with PAT growing 36.7% year-on-year. - The new API block and R&D facility expected to start by June-July 2023 are anticipated to contribute to growth. - EPS for nine months stands at INR 31.85, with quarterly EPS at INR 6.75. - R&D expenses may increase as a percentage of sales to maintain competitive advantage, supporting future earnings growth. - The capex plan of INR 200 crores over 2-3 years aims for healthy ROI rather than specific turnover targets.

- The company acknowledged delays in government and global tenders, particularly impacting Rifamycin-S sales, as it is a tender-driven segment. - Despite subdued sales in the recent quarter, production levels have been maintained to build inventory in anticipation of tender finalizations. - Management expects the tuberculosis market tenders to open up in the next two quarters, leading to significant volume increases. - Sales momentum is expected to stabilize and improve as tender processes finalize. - There was no specific mention of a quantified current order book or pending orders value during the call. - The company advised investors to contact the Investor Relations team for detailed follow-ups regarding orders.